Show simple item record

dc.contributor.authorZinzani, Pier Luigi
dc.contributor.authorD'Amore, Francesco
dc.contributor.authorBombardieri, Emilio
dc.contributor.authorBrammer, Caroline V
dc.contributor.authorCodina, José Gómez
dc.contributor.authorIllidge, Timothy M
dc.contributor.authorJurczak, Wojciech
dc.contributor.authorLinkesch, Werner
dc.contributor.authorMorschhauser, Franck
dc.contributor.authorVandenberghe, Elisabeth
dc.contributor.authorVan Hoof, Achiel
dc.date.accessioned2009-05-12T17:58:12Z
dc.date.available2009-05-12T17:58:12Z
dc.date.issued2008-02
dc.identifier.citationConsensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. 2008, 44 (3):366-73 Eur. J. Canceren
dc.identifier.issn0959-8049
dc.identifier.pmid18194857
dc.identifier.doi10.1016/j.ejca.2007.12.008
dc.identifier.urihttp://hdl.handle.net/10541/67981
dc.description.abstractRadiolabelled immunotherapy is a significant step forward in the treatment of non-Hodgkin's lymphoma (NHL), with preliminary data suggesting long remissions in some patients. 90Y-ibritumomab tiuxetan is the only therapy approved for use after rituximab failure and is currently indicated in the EU for the treatment of adults with rituximab-relapsed or refractory CD20-positive follicular B-cell NHL. However, retrospective analyses confirm better responses when 90Y-ibritumomab tiuxetan is used earlier in the disease course. An expert panel of oncologists, haematologists and nuclear medicine physicians met at an European workshop to discuss proposed therapeutic algorithms for follicular lymphoma and the preliminary medical evidence supporting the incorporation of 90Y-ibritumomab tiuxetan as an early therapeutic option. Phase II data indicate that 90Y-ibritumomab tiuxetan either alone as primary therapy or as consolidation therapy following induction chemotherapy with or without rituximab achieves high response rates in follicular lymphoma, with complete remission rates of 62-80%. Phase III data are warranted, but based on preliminary observations the expert panel recommended incorporation of radiolabelled immunotherapy into national lymphoma treatment algorithms across Europe. This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas.
dc.language.isoenen
dc.subjectFollicular Lymphomaen
dc.subjectGuidelinesen
dc.subjectImmunotherapyen
dc.subjectNon-Hodgkin's Lymphomaen
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshClinical Trials as Topic
dc.subject.meshEurope
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLymphoma, Follicular
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshRadioimmunotherapy
dc.subject.meshRadiopharmaceuticals
dc.subject.meshTreatment Outcome
dc.titleConsensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.en
dc.typeArticleen
dc.contributor.departmentInstitute of Hematology and Oncology Seràgnoli, Via Massarenti 9, 40138 Bologna, Italy. plzinzo@med.unibo.iten
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractRadiolabelled immunotherapy is a significant step forward in the treatment of non-Hodgkin's lymphoma (NHL), with preliminary data suggesting long remissions in some patients. 90Y-ibritumomab tiuxetan is the only therapy approved for use after rituximab failure and is currently indicated in the EU for the treatment of adults with rituximab-relapsed or refractory CD20-positive follicular B-cell NHL. However, retrospective analyses confirm better responses when 90Y-ibritumomab tiuxetan is used earlier in the disease course. An expert panel of oncologists, haematologists and nuclear medicine physicians met at an European workshop to discuss proposed therapeutic algorithms for follicular lymphoma and the preliminary medical evidence supporting the incorporation of 90Y-ibritumomab tiuxetan as an early therapeutic option. Phase II data indicate that 90Y-ibritumomab tiuxetan either alone as primary therapy or as consolidation therapy following induction chemotherapy with or without rituximab achieves high response rates in follicular lymphoma, with complete remission rates of 62-80%. Phase III data are warranted, but based on preliminary observations the expert panel recommended incorporation of radiolabelled immunotherapy into national lymphoma treatment algorithms across Europe. This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas.


Files in this item

This item appears in the following Collection(s)

Show simple item record